Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Gilead Sciences (GILD) Q1 2020 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Thursday said its first-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction. The company did not provide guidance for fiscal 2020, due to the coronavirus-driven uncertainty.
First-quarter adjusted earnings increased to $1.68 per share from $1.67 per share a year earlier. Analysts were looking for a smaller bottom-line number.
Net income, on an unadjusted basis, came in at $1.55 billion or $1.22 per share, compared to $1.98 billion or $1.54 per share in the prior-year period. The improvement primarily reflects favorable tax effects and gains from equity securities.
Revenues moved up 5% year-over-year to $5.55 billion and exceeded the market’s prediction. The company’s stock closed Thursday’s regular trading higher, hut slipped into the negative territory during the after-hours session.
Most Popular
Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2
After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company started trading in double-digits after a long time.
During tough times, Tilray (TLRY) looks overseas to achieve growth targets
Cannabis was recognized as an essential business in several markets when the shutdown came into effect, including Canada and some US states, at a time when its legalization is getting
Eastman Kodak (KODK) swings to a loss in Q2 2020; revenue drops 31%
Eastman Kodak (NYSE: KODK) reported a loss of $5 million on revenue of $213 million in the second quarter of 2020. The company earned $201 million in the prior-year quarter.